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INTRODUCTION:
"The present application refines critical details required for successful cell transplantation. Aim 1 (Optimal Surgical Technique) has provided critical data on tolerance and toxicity of cell dosing and numbers of permissible spinal cord injections. Aim 2 (Graft Rejection) will provide critical data on graft rejection and appropriate immunosuppression for human spinal cord stem cell transplantation." KEYWORDS: ALS, cell therapy, escalation, graft, number, pigs, safety, spinal cord, swine, tolerance, transplantation, volume.
ACCOMPLISHMENTS:
In Year 3 we have completed histological and stereological analyses pertaining to Aim 1. We are currently performing surgical procedures pertaining to Aims 2c and 2d. A total of 25 animals have been / are planned to be used. 
IMPACT:
Data generated in Aim 1 has been "disseminated to communities of interest" and consequently assisted other research groups (Svendsen group, Q Therapeutics) in their planning for upcoming trials and IND submissions to the FDA for ALS indication.
CHANGES/PROBLEMS:
On Feb 2014, we received approval for a rebudgeting / termination of subcontract (see Appendix 1). 
SPECIAL REPORTING REQUIREMENTS:
N/A.
APPENDICES:
Appendix 1 -Abstract -Immunology Data
Appendix 2 -Summary of Aim 1 Data for Manuscript Submission
